Glycomics of pediatric and adulthood diseases of the central nervous system

Journal of Proteomics

Volumn 75, Issue 17, 2012, Pages 5123-5139

  Barone, Rita ^a   Sturiale, Luisa ^b   Palmigiano, Angelo ^b   Zappia, Mario ^a   Garozzo, Domenico ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b CNR   (Italy)

Author keywords

Alzheimer's Disease; CNS diseases; CSF; Glycomics

Indexed keywords

ADULT DISEASE; ADULTHOOD; AGING; ALZHEIMER DISEASE; ATAXIA; ATTENTION DEFICIT DISORDER; AUTISM; CENTRAL HYPOMYELINATION; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CHILDHOOD DISEASE; CONGENITAL DISORDER OF GLYCOSYLATION; DEMENTIA; DEMYELINATING DISEASE; GERIATRIC PATIENT; GLYCOBIOLOGY; GLYCOSYLATION; HUMAN; MENTAL DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; VANISHING WHITE MATTER DISEASE;

ADULT; AGE OF ONSET; AGING; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; GLYCOMICS; GLYCOSYLATION; HUMANS; MODELS, BIOLOGICAL;

EID: 84865541699     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.07.007     Document Type: Review

References (106)

1. Lowe J.B., Marth J.D. A genetic approach to mammalian glycan function. Annu Rev Biochem 2003, 72:643-669.
2. Kleene R., Schachner M. Glycans and neural cell interactions. Nat Rev Neurosci 2004, 5:195-208.
3. Ohtsubo K., Marth J.D. Glycosylation in cellular mechanisms of health and disease. Cell 2006, 126:855-867.
4. Spiro R.G. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 2002, 12:43R-56R.
5. Kornfeld R., Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 1985, 54:631-664.
6. Okajima T., Irvine K.D. Regulation of notch signalling by O-linked fucose. Cell 2002, 111:893-904.
7. Endo T. Structure, function and pathology of O-mannosyl glycans. Glycoconj J 2004, 21:3-7.
8. Freeze H.H., Sharma V. Metabolic manipulation of glycosylation disorder in human and animal models. Semin Cell Dev Biol 2010, 21:655-662.
9. Hu H., Li J., Gagen C.S., Gray N.W., Zhang Z., Qi Y., et al. Conditional knockout of protein O-mannosyltransferase 2 reveals tissue-specific roles of O-mannosyl glycosylation in brain development. J Comp Neurol 2011, 519:1320-1337.
10. Ryberg H., An J., Darko S., Lustgarten J.L., Jaffa M., Gopalakrishnan V., et al. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve 2010, 42:104-111.
11. Dumont D., Noben J.P., Raus J., Stinissen P., Robben J. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004, 4:2117-2124.
12. Tumani H., Lehmensiek V., Lehnert S., Otto M., Brettschneider J. 2D DIGE of the cerebrospinal fluid proteome in neurological diseases. Expert Rev Proteomics 2010, 7:29-38.
13. Qualtieri A., Urso E., Le Pera M., Sprovieri T., Bossio S., Gambardella A., et al. Proteomic profiling of cerebrospinal fluid in Creutzfeldt-Jakob disease. Expert Rev Proteomics 2010, 7:907-917.
14. Choi Y.S., Choe L.H., Lee K.H. Recent cerebrospinal fluid biomarker studies of Alzheimer's disease. Expert Rev Proteomics 2010, 7:919-929.
15. Jaeken J. Congenital disorders of glycosylation. Ann NY Acad Sci 2010, 1214:190-198.
16. Freeze H.H., Eklund E.A., Ng B.G., Patterson M.C. Neurology of inherited glycosylation disorders. Lancet Neurol 2012, 11:453-466.
17. Lefeber D.J., Morava E., Jaeken J. How to find and diagnose a CDG due to defective N-glycosylation. J Inherit Metab Dis 2011, 34:849-852.
18. Beckmann J.S., Estivill X., Antonarakis S.E. Copy number variants and genetic traits: closer to the resolution of phenotypic to genotypic variability. Nat Rev Genet 2007, 8:639-646.
19. Sebat J., Lakshmi B., Malhotra D., Troge J., Lese-Martin C., Walsh T., et al. Strong association of de novo copy number mutations with autism. Science 2007, 316:445-449.
20. van der Zwaag B., Franke L., Poot M., Hochstenbach R., Spierenburg H.A., Vorstman J.A., et al. Gene-network analysis identifies susceptibility genes related to glycobiology in autism. PLoS One 2009, 4:e5324.
21. Liu F., Iqbal K., Grundke-Iqbal I., Hart G.W., Gong C.X. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A 2004, 101:1084-1089.
22. Liu Y., Liu F., Grundke-Iqbal I., Iqbal K., Gong C.X. Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem 2009, 111:242-249.
23. Halim A., Brinkmalm G., Rüetschi U., Westman-Brinkmalm A., Portelius E., Zetterberg H., et al. Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. Proc Natl Acad Sci U S A 2011, 108:11848-11853.
24. Akasaka-Manya K., Manya H., Sakurai Y., Wojczyk B.S., Spitalnik S.L., Endo T. Increased bisecting and core-fucosylated N-glycans on mutant human amyloid precursor proteins. Glycoconj J 2008, 25:775-786.
25. Akasaka-Manya K., Manya H., Sakurai Y., Wojczyk B.S., Kozutsumi Y., Saito Y., et al. Protective effect of N-glycan bisecting GlcNAc residues on beta-amyloid production in Alzheimer's disease. Glycobiology 2010, 20:99-106.
26. Botella-López A., Burgaya F., Gavín R., García-Ayllón M.S., Gómez-Tortosa E., Peña-Casanova J., et al. Reelin expression and glycosylation patterns are altered in Alzheimer's disease. Proc Natl Acad Sci U S A 2006, 103(14):5573-5578.
27. Sáez-Valero J., Fodero L.R., Sjögren M., Andreasen N., Amici S., Gallai V., et al. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. J Neurosci Res 2003, 72:520-526.
28. Mariño K., Bones J., Kattla J.J., Rudd P.M. A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol 2010, 6:713-723.
29. Margolis R.U., Margolis R.K. Neurobiology of glycoconjugates 1989, Plenum Press, New York.
30. Hoffmann A., Nimtz M., Wurster U., Conradt H.S. Carbohydrate structures of β-trace protein from human cerebrospinal fluid: evidence for "brain-type" N-glycosylation. J Neurochem 1994, 63:2185-2196.
31. Hoffmann A., Nimtz M., Getzlaff R., Conradt H.S. 'Brain-type' N-glycosylation of asialo-transferrin from human cerebrospinal fluid. FEBS Lett 1995, 359:164-168.
32. Mochel F., Sedel F., Vanderver A., Engelke U.F., Barritault J., Yang B.Z., et al. Cerebellar ataxia with elevated cerebrospinal free sialic acid (CAFSA). Brain 2009, 132:801-809.
33. Nakamura N., Lyalin D., Panin V.M. Protein O-mannosylation in animal development and physiology: from human disorders to Drosophila phenotypes. Semin Cell Dev Biol 2010, 21:622-630.
34. Jaeken J. Congenital disorders of glycosylation (CDG): it's (nearly) all in it!. J Inherit Metab Dis 2011, 34:853-858.
35. Jaeken J., Matthijs G. Congenital disorders of glycosylation: a rapidly expanding disease family. Annu Rev Genomics Hum Genet 2007, 8:261-278.
36. Barone R., Sturiale L., Garozzo D. Mass spectrometry in the characterization of human genetic N-glycosylation defects. Mass Spectrom Rev 2009, 28:517-542.
37. Wada Y., Gu J., Okamoto N., Inui K. Diagnosis of carbohydrate-deficient glycoprotein syndrome by matrix-assisted laser desorption time-of-flight mass spectrometry. Biol Mass Spectrom 1994, 23:108-109.
38. Wada Y., Nishikawa A., Okamoto N., Inui K., Tsukamoto H., Okada S., et al. Structure of serum transferrin in carbohydrate-deficient glycoprotein syndrome. Biochem Biophys Res Commun 1992, 189:832-836.
39. Zeevaert R., Foulquier F., Jaeken J., Matthijs G. Deficiencies in subunits of the Conserved Oligomeric Golgi (COG) complex define a novel group of Congenital Disorders of Glycosylation. Mol Genet Metab 2008, 93:15-21.
40. Reynders E., Foulquier F., Leão Teles E., Quelhas D., Morelle W., Rabouille C., et al. Golgi function and dysfunction in the first COG4-deficient CDG type II patient. Hum Mol Genet 2009, 18:3244-3256.
41. Sturiale L., Barone R., Palmigiano A., Ndosimao C.N., Briones P., Adamowicz M., et al. Multiplexed glycoproteomic analysis of glycosylation disorders by sequential yolk immunoglobulins immunoseparation and MALDI-TOF MS. Proteomics 2008, 8:3822-3832.
42. Sturiale L., Barone R., Garozzo D. The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation. J Inherit Metab Dis 2011, 34:891-899.
43. Pohl S., Hoffmann A., Rüdiger A., Nimtz M., Jaeken J., Conradt H.S. Hypoglycosylation of a brain glycoprotein (beta-trace protein) in CDG syndromes due to phosphomannomutase deficiency and N-acetylglucosaminyl-transferase II deficiency. Glycobiology 1997, 7:1077-1084.
44. Grünewald S., Huyben K., de Jong J.G., Smeitink J.A., Rubio E., Boers G.H., et al. beta-Trace protein in human cerebrospinal fluid: a diagnostic marker for N-glycosylation defects in brain. Biochim Biophys Acta 1999, 1455:54-60.
45. Jaeken J., Carchon H., Stibler H. The carbohydrate-deficient glycoprotein syndromes: pre-Golgi and Golgi disorders?. Glycobiology 1993, 3:423-428.
46. Schiffmann R., Elroy-Stein O. Childhood ataxia with CNS hypomyelination/vanishing white matter disease-a common leukodystrophy caused by abnormal control of protein synthesis. Mol Genet Metab 2006, 88:7-15.
47. Sutton-Smith M., Morris H.R., Grewal P.K., Hewitt J.E., Bittner R.E., Goldin E., et al. MS screening strategies: investigating the glycomes of knockout and myodystrophic mice and leukodystrophic human brains. Biochem Soc Symp 2002, 69:105-115.
48. Vanderver A., Schiffmann R., Timmons M., Kellersberger K.A., Fabris D., Hoffman E.P., et al. Decreased asialotransferrin in cerebrospinal fluid of patients with childhood-onset ataxia and central nervous system hypomyelination/vanishing white matter disease. Clin Chem 2005, 51:2031-2042.
49. Butler M., Quelhas D., Critchley A.J., Carchon H., Hebestreit H.F., Hibbert R.G., et al. Detailed glycan analysis of serum glycoproteins of patients with congenital disorders. Glycobiology 2003, 13:601-622.
50. Gallo P., Bracco F., Morara S., Battistin L., Tavolato B. The cerebrospinal fluid transferrin/tau proteins. A study by two-dimensional polyacrylamide gel electrophoresis (2D) and agarose isoelectrofocusing (IEF) followed by double-antibody peroxidase labeling and avidin-biotin amplification. J Neurol Sci 1985, 70:81-92.
51. Bauer D., Haroutunian V., Meador-Woodruff J.H., McCullumsmith R.E. Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizophr Res 2010, 117:92-98.
52. Baysal B.E., Willett-Brozick J.E., Badner J.A., Corona W., Ferrell R.E., Nimgaonkar V.L., et al. A mannosyltransferase gene at 11q23 is disrupted by a translocation breakpoint that co-segregates with bipolar affective disorder in a small family. Neurogenetics 2002, 4:43-53.
53. Sharp S.I., McQuillin A., Gurling H.M. Genetics of attention-deficit hyperactivity disorder (ADHD). Neuropharmacology 2009, 590-600.
54. Pivac N., Knezević A., Gornik O., Pucić M., Igl W., Peeters H., et al. Human plasma glycome in attention-deficit hyperactivity disorder and autism spectrum disorders. Mol Cell Proteomics 2010, [Epub ahead of print].
55. Dennis J.W., Lau K.S., Demetrious M., Nabi I.R. Adaptive regulation at the cell surface by N-glycosylation. Traffic 2009, 10:1569-1578.
56. Partridge E.A., Le Roy C., Di Guglielmo G.M., Pawling J., Cheung P., Granovsky M., et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 2004, 306:120-124.
57. Sato Y., Endo T. Alteration of brain glycoproteins during aging. Geriatr Gerontol Int 2010, 10:S32-S40.
58. Parekh R., Roitt I., Isenberg D., Dwek R., Rademacher T. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med 1988, 167:1731-1736.
59. Vanhooren V., Desmyter L., Liu X.E., Cardelli M., Franceschi C., Federico A., et al. N-glycomic changes in serum proteins during human aging. Rejuvenation Res 2007, 10:521a-531a.
60. Vanhooren V., Laroy W., Libert C., Chen C. N-glycan profiling in the study of human aging. Biogerontology 2008, 351-356.
61. Vanhooren V., Dewaele S., Libert C., Engelborghs S., De Deyn P.P., Toussaint O., et al. Serum N-glycan profile shift during human ageing. Exp Gerontol 2010, 45:738-743.
62. Ding N., Nie H., Sun X., Sun W., Qu Y., Liu X., et al. Human serum N-glycan profiles are age and sex dependent. Age Ageing 2011, 40:568-575.
63. Knezevic A., Gornik O., Polasek O., Pucic M., Redzic I., Novokmet M., et al. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. Glycobiology 2010, 20:959-969.
64. Ruhaak L.R., Uh H.W., Beekman M., Hokke C.H., Westendorp R.G., Houwing-Duistermaat J., et al. Plasma protein N-glycan profiles are associated with calendar age, familial longevity and health. J Proteome Res 2011, 10:1667-1674.
65. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
66. Urakami K. Diagnostic biomarker for early stage of Alzheimer's disease: current state and view in the future. Psychogeriatrics 2010, 10:49-52.
67. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001, 58:373-379.
68. Ibach B., Binder H., Dragon M., Poljansky S., Haen E., Schmitz E., et al. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 2006, 27:1202-1211.
69. Wallin A., Göthlin M., Gustavsson M., Zetterberg H., Eckerström C., Blennow K., et al. Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations. Dement Geriatr Cogn Disord 2011, 32:193-197.
70. Fatemi S.H., Snow A.V., Stary J.M., Araghi-Niknam M., Reutiman T.J., Lee S., et al. Reelin signaling is impaired in autism. Biol Psychiatry 2005, 57:777-787.
71. Sáez-Valero J., Costell M., Sjögren M., Andreasen N., Blennow K., Luque J.M. Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease. J Neurosci Res 2003, 72:132-136.
72. Kanninen K., Goldsteins G., Auriola S., Alafuzoff I., Koistinaho J. Glycosylation changes in Alzheimer's disease as revealed by a proteomic approach. Neurosci Lett 2004, 367:235-240.
73. Semenov A.G., Postnikov A.B., Tamm N.N., Seferian K.R., Karpova N.S., Bloshchitsyna M.N., et al. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem 2009, 55:489-498.
74. Perdivara I., Petrovich R., Allinquant B., Deterding L.J., Tomer K.B., Przybylski M. Elucidation of O-glycosylation structures of the beta-amyloid precursor protein by liquid chromatography-mass spectrometry using electron transfer dissociation and collision induced dissociation. J Proteome Res 2009, 8:631-642.
75. Fiala M., Liu P.T., Espinosa-Jeffrey A., Rosenthal M.J., Bernard G., Ringman J.M., et al. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci U S A 2007, 104:12849-12854.
76. Davidsson P., Ekman R., Blennow K. A new procedure for detecting brain-specific proteins in cerebrospinal fluid. J Neural Transm 1997, 104:711-720.
77. Golabek A., Marques M.A., Lalowski M., Wisniewski T. Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett 1995, 191:79-82.
78. Hansson S.F., Andréasson U., Wall M., Skoog I., Andreasen N., Wallin A., et al. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis 2009, 16:389-397.
79. Sihlbom C., Davidsson P., Nilsson C.L. Prefractionation of cerebrospinal fluid to enhance glycoprotein concentration prior to structural determination with FT-ICR mass spectrometry. J Proteome Res 2005, 4:2294-2301.
80. Sihlbom C., Davidsson P., Sjögren M., Wahlund L.O., Nilsson C.L. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's Disease patients and healthy individuals. Neurochem Res 2008, 33:1332-1340.
81. Puchades M., Hansson S.F., Nilsson C.L., Andreasen N., Blennow K., Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 2003, 118:140-146.
82. Sihlbom C., Davidsson P., Emmett M.R., Marshall A.G., Nilsson C.L. Glycoproteomics of cerebrospinal fluid in neurodegenerative disease. Int J Mass Spectrom 2004, 234:145-152.
83. Mao X., Luo Y., Dai Z., Wang K., Du Y., Lin B. Integrated lectin affinity microfluidic chip for glycoform separation. Anal Chem 2004, 76:6941-6947.
84. Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wiśniewski J.R. Screening for N-glycosylated proteins by liquid chromatography mass spectrometry. Proteomics 2004, 4:454-465.
85. Wang Y., Wu S.L., Hancock W.S. Approaches to the study of N-linked glycoproteins in human plasma using lectin affinity chromatography and nano-HPLC coupled to electrospray linear ion trap-Fourier transform mass spectrometry. Glycobiology 2006, 16:514-523.
86. Hirabayashi J., Kuno A., Tateno H. Lectin-based structural glycomics: a practical approach to complex glycans. Electrophoresis 2011, 32:1118-1128.
87. Pan S., Wang Y., Quinn J.F., Peskind E.R., Waichunas D., Wimberger J.T., et al. Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach. J Proteome Res 2006, 5:2769-2779.
88. Fodero L.R., Sáez-Valero J., Barquero M.S., Marcos A., McLean C.A., Small D.H. Wheat germ agglutinin-binding glycoproteins are decreased in Alzheimer's disease cerebrospinal fluid. J Neurochem 2001, 79:1022-1026.
89. Taniguchi M., Okayama Y., Hashimoto Y., Kitaura M., Jimbo D., Wakutani Y., et al. Sugar chains of cerebrospinal fluid transferrin as a new biological marker of Alzheimer's disease. Dement Geriatr Cogn 2008, 26:117-122.
90. Futakawa S., Nara K., Miyajima M., Kuno A., Ito H., Kaji H., et al. A unique N-glycan on human transferrin in CSF: a possible biomarker for iNPH. Neurobiol Aging 2011, [Epub ahead of print].
91. Shirotani K., Futakawa S., Nara K., Hoshi K., Saito T., Tohyama Y., et al. High throughput ELISAs to measure a unique glycan on transferrin in cerebrospinal fluid: a possible extension toward Alzheimer's disease biomarker development. Int J Alzheimers Dis 2011, [Epub ahead of print].
92. Butterfield D.A., Owen J.B. Lectin-affinity chromatography brain glycoproteomics and Alzheimer disease: insights into protein alterations consistent with the pathology and progression of this dementing disorder. Proteomics Clin Appl 2011, 5:50-56.
93. Owen J.B., Di Domenico F., Sultana R., Perluigi M., Cini C., Pierce W.M., et al. Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD. J Proteome Res 2009, 8:471-482.
94. Di Domenico F., Owen J.B., Sultana R., Sowell R.A., Perluigi M., Cini C., et al. The wheat germ agglutinin-fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: implications for disease pathogenesis and progression. J Neurosci Res 2010, 88:3566-3577.
95. Chen C.C., Engelborghs S., Dewaele S., Le Bastard N., Martin J.J., Vanhooren V., et al. Altered serum glycomics in Alzheimer disease: a potential blood biomarker?. Rejuvenation Res 2010, 13:439-444.
96. International Multiple Sclerosis Genetics Consortium, Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007, 357:851-862.
97. Demetriou M., Granovsky M., Quaggin S., Dennis J.W. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 2001, 409:733-739.
98. Lee S.U., Grigorian A., Pawling J., Chen I.J., Gao G., Mozaffar T., et al. N-glycan processing deficiency promotes spontaneous inflammatory demyelination and neurodegeneration. J Biol Chem 2007, 282:33725-33734.
99. Schachter H. Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides. Biochem Cell Biol 1986, 64:163-181.
100. Mkhikian H., Grigorian A., Li C.F., Chen H.L., Newton B., Zhou R.W., et al. Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat Commun 2011, 2:334.
101. Green R.S., Stone E.L., Tenno M., Lehtonen E., Farquhar M.G., Marth J.D. Mammalian N-glycan branching protects against innate immune self-recognition and inflammation in autoimmune disease pathogenesis. Immunity 2007, 27:308-320.
102. Robotti A., Natale M., Albo A.G., Lis K., Perga S., Marnetto F., et al. Acute-phase proteins investigation based on lectins affinity capture prior to 2-DE separation: application to serum from multiple sclerosis patients. Electrophoresis 2010, 31:2882-2893.
103. Tienari P., Wynne L.C., Sorri A., Lahti I., Läksy K., Moring J., et al. Genotype-environment interaction in schizophrenia-spectrum disorder. Long-term follow-up study of Finnish adoptees. Br J Psychiatry 2004, 184:216-222.
104. Riley B., Kendler K.S. Molecular genetic studies of schizophrenia. Eur J Hum Genet 2006, 14:669-680.
105. Stanta J.L., Saldova R., Struwe W.B., Byrne J.C., Leweke F.M., Rothermund M., et al. Identification of N-glycosylation changes in the CSF and serum in patients with schizophrenia. J Proteome Res 2010, 9:4476-4489.
106. Narayan S., Head S.R., Gilmartin T.J., Dean B., Thomas E.A. Evidence for disruption of sphingolipid metabolism in schizophrenia. J Neurosci Res 2009, 87:278-288.